Loading stock data…
ACOG
$5.95-0.02 (-0.34%)
Market ClosedLast close May 1
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alpha Cognition Inc. Common Stock in the Healthcare sector is trading at $5.95. The stock is currently 48% below its 52-week high of $11.54, remaining 12.5% below its 200-day moving average. Technical signals show neutral RSI of 50 and bearish MACD signal, explaining why ACOG maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.95
Potential Upside
5%
Whystock Fair Value$6.25
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$16.00+168.9%
Range$14.00 – $18.00
Fundamentals
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tab...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$148.06M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.52
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-33.06%
Volume
Today's trading volume
17,802
Recent News
Alpha Cognition Inc.'s (NASDAQ:ACOG) Path To Profitability
We feel now is a pretty good time to analyse Alpha Cognition Inc.'s ( NASDAQ:ACOG ) business as it appears the company...
Alpha Cognition Inc. (ACOG) Soars 8.6%: Is Further Upside Left in the Stock?
Alpha Cognition Inc. (ACOG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Alpha Cognition (ACOG) Q4 2025 Earnings Transcript
Good afternoon, and thank you, everyone, for joining us today for Alpha Cognition's Fourth Quarter and Full Year Fiscal 2025 Results Call. Today, after the close of market, the company issued a press release announcing our financial results. Joining me on the call today are Alpha Cognition's Chief Executive Officer, Michael McFadden; and Chief Operating Officer, Lauren D'Angelo.
Alpha Cognition Inc. Common Stock Q4 2025 Earnings Call Summary
Moby summary of Alpha Cognition Inc. Common Stock's Q4 2025 earnings call
Alpha Cognition Q4 Earnings Call Highlights
Alpha Cognition (NASDAQ:ACOG) executives told investors the company is seeing continued sales growth and what it described as accelerating, durable adoption following the commercial launch of ZUNVEYL, an oral treatment approved for mild to moderate Alzheimer’s disease. Management emphasized early de